Market Overview

UPDATE: Morgan Stanley Downgrades St. Jude Medical to Equal-Weight on Pipeline Outlook

Related STJ
Abbott Labs Has 'An Emerging Picture Of Top-Tier Growth,' Says Morgan Stanley
Dept. of Homeland Security Provides A Timely Update On Abbott, St. Jude

Morgan Stanley lowered its rating on St. Jude Medical (NYSE: STJ) from Overweight to Equal-weight and removed its previous $52 price target.

Morgan Stanley commented, "We are downgrading to Equal-weight with a base case of $42 because the growth acceleration component of our thesis is less likely to materialize. … A weaker pipeline outlook and slower CRM recovery make 2013 sales acceleration less likely. Our prior view was based on a five year pipeline analysis, but required near-term catalysts to improve visibility. We expected a CRM recovery and pipeline execution to drive a sales growth inflection into 2013 and subsequent multiple re-rating. Diligence at the TCT cardiology conference reduced our enthusiasm for multiple pipeline programs, and CRM remains sluggish."

St. Jude Medical closed at $38.29 on Friday.

Latest Ratings for STJ

Jul 2016WedbushDowngradesOutperformNeutral
Jul 2016Leerink SwannDowngradesOutperformMarket Perform
May 2016BarclaysDowngradesOverweightEqual-Weight

View More Analyst Ratings for STJ
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings


Related Articles (STJ)

View Comments and Join the Discussion!